glp-1 and brain health Could diabetes weight loss drugs treat Alzheimer's disease? GLP-1 Injections for Medical Weight

Inhibiting the PI3K/Akt signaling pathway may eliminate the protective effect of GLP-1R by increasing ER stress, suggesting that this pathway may be involved in the effect of GLP-1 on ER stress

Extended use beyond 16 weeks may desensitize GH receptors

Healthcare professionals such as nurses, pharmacists, and clinicians who want to learn safe injection practices

Petrelintide (ZP8396) Petrelintide (ZP8396) is a novel SC-administered, long-acting amylin analog, developed by Zealand Pharma (Sborg, Denmark), a peptide drug discovery and development company, which is currently in early-stage clinical trials (phase 1 clinical trials: ClinicalTrials.gov Identifier NCT05511025, NCT05096598 and NCT05613387) [116]